Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

Sleep Disturbance Clinical Trial

Official title:

Examining the Role of the Orexin System in Sleep and Stress in Persons With Opioid Use Disorder

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04287062
• Other study ID #: IRB00223942
• Secondary ID: U01HL150835
• Status: Recruiting
• Phase: Phase 2
• Start date: November 20, 2020
• Est. completion date: August 2024

Study information

• Verified date: August 2023
• Source: Johns Hopkins University
• Contact: Andrew S Huhn, PhD
• Phone: 410-550-1971
• Email: ahuhn1[@]jhu.edu
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is designed to elucidate the role of the orexin neurotransmitter system in sleep disturbance and circadian rhythms of stress that might in turn influence relapse behaviors in persons on medication-assisted treatments (MAT) who are in early recovery from opioid use disorder (OUD). Briefly, the study will enroll recently abstinent OUD patients (N=200) maintained on either extended-release naltrexone (XR-NTX), buprenorphine, or methadone. Within each MAT group, participants will be randomized to either suvorexant or placebo. The study is expected to have a 20% treatment attrition rate which will result in N=160 completers in the entire study. Patients will be recruited from and treated at Ashley Addiction Treatment, Addiction Treatment Services at Johns Hopkins Bayview Medical Center, Man Alive, or community providers.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 200
• Est. completion date: August 2024
• Est. primary completion date: August 2024
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Between the ages of 21-65, inclusive.

• Past 30-day sleep disturbance as evidenced by a Pittsburgh Sleep Quality Index Total Score >5.

• Enrolled in either outpatient methadone-maintenance, buprenorphine-maintenance, or XR-NTX treatment for OUD.

• Willingness to be maintained on a protocolized dose starting between 60-130mg methadone or 380mg XR-NTX for the duration of the study.

• At least two weeks of continuous abstinence from illicit opioids as evidenced by self-report and urine drug screens collected as part of routine care.

• Willing to comply with the study protocol, which will include weekly study visits, daily actigraphy and ecological momentary assessments.

• Use of birth control throughout study.

• Have no clinically significant chronic medical disorders or conditions that are judged by the investigators to prevent participation.

Exclusion Criteria:

• Serious mental illnesses that are unstable and could affect study participation (thought disorders, hallucinations, delusions, thoughts of harm to self/others).

• Current moderate to severe substance use disorder other than OUD.

• Current illicit stimulant use, including cocaine and methamphetamine.

• Pregnant or breast feeding.

• Have a known allergy to the study medications.

• Past 30-day prescribed use of suvorexant.

• Current use of a benzodiazepine or other schedule IV medication for insomnia.

• Use of Cytochrome P450 3A inhibitors.

• Current narcolepsy, sleep paralysis, or restless leg syndrome as assessed by medical history

• Apnea-hypopnea index > 30.

• Use of glucocorticoid medications and any medication that would alter the hypothalamic-pituitary-adrenal axis.

• Past 30-day suicidal behavior as assessed by the Columbia Suicide Severity Rating Scale (C-SSRS).

• Have circumstances that would interfere with study participation (e.g., impending jail; severe clinical issues).

Related Conditions & MeSH terms

• Dyssomnias
• Opioid-Related Disorders
• Opioid-use Disorder
• Parasomnias
• Sleep Disturbance
• Substance-Related Disorders

Intervention

Drug:
• Suvorexant
Dual orexin receptor antagonist
• Placebos
Weight and color matched placebo

Locations

Country	Name	City	State
United States	Addiction Treatment Services at Johns Hopkins Bayview Medical Center	Baltimore	Maryland
United States	Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center	Baltimore	Maryland
United States	Man Alive Inc., Lane Treatment Center	Baltimore	Maryland
United States	Ashley Addiction Treatment	Bel Air	Maryland
United States	Ashley Addiction Treatment	Elkton	Maryland

Sponsors (2)

Lead Sponsor	Collaborator
Johns Hopkins University	National Heart, Lung, and Blood Institute (NHLBI)

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Total Sleep Time	Mean total number of minutes slept per night as measured by actigraphy and self-reported sleep diary. Mean total sleep time will be collected over a seven-night period in weeks 1, 4, and 8 of the trial.	21 nights
Primary	Total Wake Time After Sleep Onset	Mean total number of minutes awake between initial sleep onset and final morning awakening, measured by actigraphy and self-reported sleep diary. Mean wake after sleep onset will be collected over a seven-night period in weeks 1, 4, and 8 of the trial.	21 nights
Primary	Change in Perceived Stress Scale 4 (PSS-4) score	Mean daily scores on the PSS-4 (a four item scale self-reported scale than measures stress using a 0-4 Likert scale; total range of PSS-4 scores is 0-16; lower scores indicate lower daily stress relative to higher scores, which indicate higher daily stress). Mean PSS-4 scores will be collected over a seven-day period in weeks 1, 4, and 8 of the trial.	21 days (collected over a seven-day period in weeks 1, 4, and 8 of the trial)